Tesamorelin
GHRH analog approved in some regions for HIV-associated lipodystrophy visceral fat.
Overview
Distinct indication from cosmetic fat loss — requires specialist care.
What it is
Synthetic GHRH(1-44) analog with daily dosing.
Mechanism (high level)
Increases endogenous GH and IGF-1; monitor glucose and IGF-1 on therapy.
Quick facts
- Dosage
- Per label — daily SubQ
- Route
- Subcutaneous abdominal
- Cycle
- Chronic while indicated
- Storage
- Refrigerate
Research indications
- HIV-associated excess visceral adiposity (where approved)
Research protocols (education)
Education-first logging template
Use PepTok to track adherence and notes; any protocol must be directed by a qualified clinician.
Interactions
Often avoided with
- Active malignancy
- prader-willi syndrome
Often combined with
- Glucose monitoring
- IGF-1 labs
Peptides discussed online are not substitutes for diagnosis or prescriptions.
Side effects & safety
- Peripheral edema, joint pain, glucose elevation — IGF-1 monitoring required.
Regulatory notes
- FDA-approved for specific HIV-associated indication in the US.
FAQ
Is this a prescription?
PepTok does not provide prescriptions; it is for logging and education.
Related in catalog
Track in app
Save favorites, compare protocols, and track over time
PepTok gives you structure: stacks, reminders, notes, and progress snapshots in one place.
Educational content only. This material is not medical advice. Verify legality, sourcing, and dosing with a qualified professional.